rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Mereo BioPharma Group plc - American Depositary Shares

MREO · Nasdaq

Health CareBiotechnologyNot moving yet

MREO stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 1.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
56 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders56-1 on the quarter
New · exited14 · 16
Reported value$18.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Rubric Capital Management LPunchanged · filed 14 Aug 202615,307,347$4.9M00.0%
683 Capital Management, LLCreduced · filed 14 Aug 202611,777,856$3.7M-222,144−1.9%
BANK OF AMERICA CORPreduced · filed 14 Aug 20268,195,281$2.6M-60.0%
Defilade Capital Management, L.P.unchanged · filed 14 Aug 20267,558,756$2.4M00.0%
Newtyn Management, LLCreduced · filed 14 Aug 20263,000,000$953K-4,079,056−57.6%
Tejara Capital Ltdunchanged · filed 11 Aug 20262,037,520$647K00.0%
UBS Group AGreduced · filed 13 Aug 20261,447,627$460K-42,501−2.9%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 20261,319,241$419K+1,131,402+602.3%
EcoR1 Capital, LLCreduced · filed 14 Aug 20261,000,000$318K-12,368,855−92.5%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026774,944$246K+634,971+453.6%
31 Mar 2023 – 30 Jun 2026
496988Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Anders Ekblom Company insiderDirector · last 26 Feb 20260 · 0
Annalisa Jenkins Company insiderDirector · last 26 Feb 20260 · 0
Daniel Shames Company insiderDirector · last 26 Feb 20260 · 0
Deepika Pakianathan Company insiderDirector · last 26 Feb 20260 · 1
Jeremy Bender Company insiderDirector · last 26 Feb 20260 · 0
Marc J. Yoskowitz Company insiderDirector · last 26 Feb 20260 · 0
Michael S. Wyzga Company insiderDirector · last 26 Feb 20260 · 0
Pierre Jacquet Company insiderDirector · last 26 Feb 20260 · 0
Alexandra Hughes-Wilson Company insiderOfficer · last 1 Feb 20260 · 5
Charles Sermon Company insiderGeneral Counsel · last 1 Feb 20260 · 4
Christine Ann Fox Company insiderChief Financial Officer · last 1 Feb 20260 · 4
Denise Scots-Knight Company insiderChief Executive Officer · last 1 Feb 20260 · 4

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-96.4%
Share count trendFY 2025 · to 18 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$41.0M
Free cash flowFY 2025 · to 31 Dec 2025−$31.0M

Analyst forecasts

No analyst forecasts yet.